| Type | Title | Date Released | |
|---|---|---|---|
4 | Hoffman Michael B (Reporting) | ||
8-K | Annovis Bio Announces Launch of Proposed Public Offering of Common Stock and Warrants | ||
424B5 | REGISTERED OFFERING | ||
424B5 | PENDING FIXED PRICE OFFERING | Bank: Canaccord Genuity | ||
8-K | Preliminary Cash and Cash Equivalents Estimated at Approximately $2.8 Million as of September 30, 2026 | ||
8-K | Annovis Bio Holds Special Meeting and Approves Charter Amendment to Increase Authorized Common Stock | ||
8-K | Annovis Bio Receives NYSE Continued Listing Standard Notice | ||
8-K | Corrected Proxy Statement Discloses 2025 and 2024 Audit Fees of $515,000 and $482,045, Respectively | ||
SCHEDULE 13G/A | Empery Asset Management, LP (Filed by) | ||
DEFA14A | Form DEFA14A | ||
DEF 14A | Form DEF 14A | ||
PRE 14A | Form PRE 14A |
